Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.

Annals of the American Thoracic Society - 1 Nov 2017

Jennings Mark T, Dezube Rebecca, Paranjape Shruti, West Natalie E, Hong Gina, Braun Andrew, Grant Jonathan, Merlo Christian A, Lechtzin Noah

Abstract excerpt

RATIONALE: In July 2015, the U.S. Food and Drug Administration approved lumacaftor/ivacaftor for use in patients with cystic fibrosis (CF). This drug targets the primary defect in the CFTR protein that is conferred by the F508del CFTR mutation. OBJECTIVE: As there is limited experience with this therapy outside of clinical trials, this study aims to examine the clinical experience of this new drug in a population...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Combinations

Share to Dyspnea

Share to Forced Expiratory Volume

Share to Quinolones

Source

Identifiers

PMID: 28406713
DOI: 10.1513/AnnalsATS.201701-058OC

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.PMID 28406713Read ↗

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.Semantic proximity Read ↗

Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.Semantic proximity Read ↗

A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Semantic proximity Read ↗

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.Semantic proximity Read ↗

A safety evaluation of ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.Semantic proximity Read ↗

Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.Semantic proximity Read ↗

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.Semantic proximity Read ↗

Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Semantic proximity Read ↗

Tezacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.